Found: 17
Select item for more details and to access through your institution.
Exon–Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation.
- Published in:
- Non-Coding RNA, 2021, v. 7, n. 2, p. 1, doi. 10.3390/ncrna7020026
- By:
- Publication type:
- Article
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 3, p. 1060, doi. 10.3390/ijms21031060
- By:
- Publication type:
- Article
The BET Bromodomain Inhibitor (BETi) OTX015 (MK-8628) Upregulates miR-96-5p in Diffuse Large B-Cell Lymphomas (DLBCL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S105, doi. 10.1016/j.clml.2016.07.151
- By:
- Publication type:
- Article
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma.
- Published in:
- EJHaem, 2022, v. 3, n. 3, p. 764, doi. 10.1002/jha2.535
- By:
- Publication type:
- Article
The ATR inhibitor elimusertib exhibits anti‐lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 1, p. 191, doi. 10.1111/bjh.19218
- By:
- Publication type:
- Article
In vitro anti‐lymphoma activity of the first‐in‐class pan‐NOTCH transcription inhibitor CB‐103.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 5, p. 669, doi. 10.1111/bjh.18576
- By:
- Publication type:
- Article
United we stand: Double targeting of CD79B and CD20 in diffuse large B‐cell lymphoma.
- Published in:
- British Journal of Haematology, 2022, v. 199, n. 2, p. 169, doi. 10.1111/bjh.18384
- By:
- Publication type:
- Article
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP‐319 in pre‐clinical models of aggressive lymphomas.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 5, p. 595, doi. 10.1111/bjh.16118
- By:
- Publication type:
- Article
In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 1, p. 149, doi. 10.1111/bjh.15727
- By:
- Publication type:
- Article
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 6, p. 936, doi. 10.1111/bjh.14803
- By:
- Publication type:
- Article
The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models.
- Published in:
- British Journal of Haematology, 2015, v. 171, n. 3, p. 378, doi. 10.1111/bjh.13595
- By:
- Publication type:
- Article
Thinking Outside the Box: Indirect Myc Modulation in Canine B-Cell Lymphoma.
- Published in:
- Animals (2076-2615), 2024, v. 14, n. 10, p. 1466, doi. 10.3390/ani14101466
- By:
- Publication type:
- Article
PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients.
- Published in:
- Cancers, 2021, v. 13, n. 21, p. 5535, doi. 10.3390/cancers13215535
- By:
- Publication type:
- Article
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.
- Published in:
- Cancers, 2019, v. 11, n. 6, p. 775, doi. 10.3390/cancers11060775
- By:
- Publication type:
- Article
Discovery Science highlights from the 17th International Conference on Malignant Lymphoma.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 3, p. 1, doi. 10.1002/hon.3275
- By:
- Publication type:
- Article
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 2, p. 399, doi. 10.3390/jcm12020399
- By:
- Publication type:
- Article
EGF and TGF-β1 Effects on Thyroid Function.
- Published in:
- Journal of Thyroid Research, 2011, p. 1, doi. 10.4061/2011/431718
- By:
- Publication type:
- Article